Screener
GRAIL, Inc. GRAL Screening revenue — Cost of revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by GRAIL, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: GRAIL, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054307
| Line item | Three Months Ended / June 30,2026 | Three Months Ended / June 30,2025 | Six Months Ended / June 30,2026 | Six Months Ended / June 30,2025 |
|---|---|---|---|---|
| Development services revenue | 2,045 | 1,165 | 2,998 | 3,869 |
| Total revenue | 44,687 | 35,544 | 85,472 | 67,381 |
| Costs and operating expenses: | ||||
| Cost of screening revenue (exclusive of amortization of intangible assets) | 23,347 | 19,346 | 44,591 | 36,469 |
| Cost of development services revenue | 434 | 501 | 810 | 1,672 |
| Cost of revenue — amortization of intangible assets | 33,472 | 33,472 | 66,944 | 66,944 |
| Research and development | 47,429 | 46,626 | 95,450 | 100,251 |
| Sales and marketing | 37,657 | 28,539 | 68,325 | 63,518 |
Item 1. Financial Statements
FAQ
- What is GRAIL, Inc.'s screening revenue — cost of revenue?
- GRAIL, Inc. (GRAL) reported screening revenue — cost of revenue of $23.35M in Q2 2026.
- How has GRAIL, Inc.'s screening revenue — cost of revenue changed year-over-year?
- GRAIL, Inc.'s screening revenue — cost of revenue increased by 20.7% year-over-year, from $19.35M to $23.35M.
- What is the long-term trend for GRAIL, Inc.'s screening revenue — cost of revenue?
- Over 3 years (2022 to 2025), GRAIL, Inc.'s screening revenue — cost of revenue has grown at a 31.6% compound annual growth rate (CAGR), from $32.14M to $73.25M.
- What does screening revenue — cost of revenue mean?
- This metric captures the direct costs associated with providing diagnostic screening services, including laboratory processing, materials, and personnel directly involved in test delivery. It is a critical measure of operational efficiency and the direct expense required to generate screening-related income. Monitoring this helps assess the gross margin potential and the cost-to-serve profile of the company's diagnostic offerings.
Ask your AI about GRAIL, Inc.'s screening revenue — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude